Instrument Inactif

Communiqués StemCells Inc Nasdaq

Actions

US85857R2040

Recherche biotechnologique et médicale

Cours en clôture Nasdaq
- ^USD	-

14/08	Microbot Medical Inc. : B. Riley persiste à l'achat	ZM
11/08	Microbot Medical Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

11/08	Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter	GL
21/07	Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting	GL
07/07	Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026	GL
30/06	Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader	GL
25/06	Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System	GL
25/06	Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System	AQ
23/06	Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System	GL
17/06	Microbot Medical Enters into an Agreement to Expand Access for America's Veteran and Military Patient Populations	AQ
16/06	Microbot Medical® Enters Into an Agreement to Expand Access for America’s Veteran and Military Patient Populations	GL
09/06	Microbot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System	GL
02/06	Microbot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System	GL
26/05	Microbot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic System	GL
15/05	Microbot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary Bercu	GL
14/05	Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026	GL
05/05	Microbot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites	GL
01/05	Microbot Medical Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia	AQ
30/04	Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)	GL
22/04	Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®	GL
15/04	Microbot Medical to Highlight Commercial Achievements Leading to the Full Market Release of the LIBERTY Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference	AQ
14/04	Microbot Medical® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference	GL
13/04	Microbot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting	GL
26/03	Emory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®’s LIBERTY® Endovascular Robotic System	GL
26/03	Emory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®’s LIBERTY® Endovascular Robotic System	AQ
24/03	Microbot Medical® Strengthens LIBERTY® Endovascular Robotic System Position with Publication of its ACCESS PVI Pivotal Study in Leading Peer-Reviewed Medical Journal	GL
17/03	Microbot Medical® to Participate at the 38th Annual Roth Conference	GL